Panelists discuss how bempedoic acid offers a promising alternative for patients who are statin-intolerant patients, demonstrating efficacy in reducing major cardiovascular events and low-density lipoproteinLDL cholesterol, while addressing its role in managing residual cardiovascular risk, particularly in high-risk populations.
Navigating Lifestyle and Pharmacotherapy Interventions in Dyslipidemia Management
December 23rd 2024Panelists discuss how lifestyle interventions, including diet, physical activity, and smoking cessation, complement pharmacotherapy in the management of dyslipidemia, and explore unmet needs in cardiovascular risk reduction, highlighting the role of emerging therapies such as bempedoic acid, inclisiran, and gene editing technologies.
Navigating Lifestyle and Pharmacotherapy Interventions in Dyslipidemia Management
January 8th 2025Panelists discuss how lifestyle interventions, including diet, physical activity, and smoking cessation, complement pharmacotherapy in the management of dyslipidemia, and explore unmet needs in cardiovascular risk reduction, highlighting the role of emerging therapies such as bempedoic acid, inclisiran, and gene editing technologies.
2 Commerce Drive
Cranbury, NJ 08512